AIM Our previous "J-BENEFIT (Japan BEzafibrate cliNical EFfectIveness and Tolerability)" study demonstrated that bezafibrate improves blood lipid profiles and glucose control in dyslipidemic patients with diabetes. However, bezafibrate did not significantly improve low-density lipoprotein cholesterol (LDL-C), although some patients showed decreases while others showed increases in the LDL-C lev...

Background: Unstable angina and myocardial infarction are developed due to atherosclerosis of coronary arteries. At present, cholestrol, triglyceride, and lipoproteins are the most common risk factors of death. The purpose of this study was to assess the serum levels of LP (a), LDL-C, VLDL-C, HDL-C in cases of unstable angina and myocardial infarction.Methods: This study was conducted to compar...

BACKGROUND Elevated low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk of cardiovascular disease or mortality; however, the LDL-C goal for therapy in acute coronary syndrome (ACS) patients is controversial and varies among guidelines. This study aimed to assess the effect of reaching an LDL-C goal of <70 mg/dL (<1.8 mmol/L) on first composite cardiovascular outcome...

Background: There is controversy whether management of blood cholesterol should be based or not on LDL-cholesterol (LDL-c) target concentrations. Objectives: To compare the estimated impact of different lipid-lowering strategies, based or not on LDL-c targets, on the risk of major cardiovascular events in a population with higher cardiovascular risk. Methods: We included consecutive individ...

BACKGROUND It has recently been shown that non-high density lipoprotein cholesterol (non-HDL-C) may be a better predictor of cardiovascular risk than low density lipoprotein cholesterol (LDL-C). Based on known ethic differences in lipid parameters and cardiovascular risk prediction, we sought to study the predictability of attaining non-HDL-C target and long-term major adverse cardiovascular ev...

Introdução: A dislipidemia é um dos principais fatores de risco da aterosclerose que, por sua vez, a principal causa morte nos países desenvolvidos, incluindo Portugal. Apesar das modificações no estilo vida e terapêutica hipolipemiante com estatina ezetimiba, muitos doentes não atingem os valores recomendados colesterol‐LDL (c-LDL). Os inibidores PCSK9 são uma nova opção que permite redução si...

Human low-density lipoproteins (LDLs) comprise a spectrum of particles that vary in size, density, chemical composition, metabolic behavior, and atherogenicity. To identify determinants of this heterogeneity, we measured the percent distribution and plasma concentration of the three major LDL subfractions in 34 young healthy subjects. These parameters were correlated in univariate and multivari...

BACKGROUND Heterozygous familial hypercholesterolemia (heFH) is a common autosomal dominant hereditary disorder caused by mutations in the LDL-receptor gene that lead to elevated plasma levels of low-density lipoprotein-cholesterol (LDL-c). Robust lowering of LDL-c levels is essential for risk reduction of premature cardiovascular diseases and early death. European and Dutch guidelines recommen...

Abstract Aim The aim of this study was to compare small dense low-density lipoprotein cholesterol (sd-LDL-c) and various lipid markers between patients exhibiting plaque rupture (PR) in the culprit lesions evaluated by optical coherence tomography (OCT) imaging those without PR ST-segment elevation myocardial infarction (STEMI) patients. Methods We studied consecutive 60 de novo with STEMI who ...